EP. 10 Counseling Patients with Multiple Myeloma on the Infection Risks of BCMA-Targeting Bispecifics
EP. 12 Advice for Patients, Nurse Practitioners, and Community Oncologists on Teclistamab Therapy in Multiple Myeloma
Toxicity Management of PI3K Pathway Inhibitors in HR+/HER2− mBCBySeth Wander, MD, PhD,Erica L. Mayer, MD, MPH,Kathryn Post, PhD, RN, ANP-BC,Jennifer Hutchinson, PharmD, BCOPSeptember 10th 2026
Treatment Strategies for Biomarker-Negative and PI3K-Pathway Altered HR+/HER2− mBCBySeth Wander, MD, PhD,Erica L. Mayer, MD, MPH,Kathryn Post, PhD, RN, ANP-BC,Jennifer Hutchinson, PharmD, BCOPSeptember 10th 2026
Etentamig Improves ORR/PFS in Relapsed/Refractory Multiple MyelomaByCancer Network StaffSeptember 4th 2026
Biomarker Testing and Treatment Selection in HR+/HER2− mBCBySeth Wander, MD, PhD,Erica L. Mayer, MD, MPH,Kathryn Post, PhD, RN, ANP-BC,Jennifer Hutchinson, PharmD, BCOPAugust 31st 2026